Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.

Horizontal portrait of David Beard

An Honorary Fellowship is the highest honour that the BOA (British Orthopaedic Association) can confer. It was awarded to Professor Beard in recognition of his outstanding contribution and achievements in research across the Trauma and Orthopaedic spectrum leading to improvements in patient care.

Professor Beard is one of the nominated Royal College of Surgeons (Eng) Surgical Trials chairs and Rosetrees Director of the Surgical Intervention Trials Unit (SITU-NDORMS) being responsible for a portfolio of surgical and complex intervention trials, many as co-applicant and some as Chief Investigator.

He is currently researching the introduction of robotic surgery in the NHS, surgical clinical trials methodology, including placebo control designs, and a host of musculoskeletal intervention efficacy studies. He is also involved in several international surgical trials and and supervises postgraduate students within NDORMS.

On being awarded the Honorary Fellowship, Professor Beard said;  

“I am very privileged and honoured to be given such a prestigious Fellowship by the BOA, especially in my core discipline, orthopaedic science. Like most personal awards the letters and certificate may point to a single name but it simply would not happen without the support and help from a set of first rate colleagues both in the Department and around the country.  To me it is very much a shared team award reflecting and recognising the success of orthopaedic/MSK research in Oxford (and the UK) over many years. Similar to everyone in NDORMS, I shall continue to do my very best research under the overall umbrella of improving healthcare, but it would give added satisfaction to see NDORMS remaining in the very top flight of those pursuing such an endeavour.” 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Adam Croft appointed Norman Collisson Professor of Musculoskeletal Science

This appointment brings a further focus to linking rheumatology discovery science and clinical trials in NDORMS, strengthening translational rheumatology research across the department to deliver transformative treatments for patients with inflammatory arthritis.

NIHR fellowship to support national trial evaluating rehabilitation after kneecap dislocation

Dr Colin Forde has been awarded a National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Postdoctoral Award to lead a national study evaluating rehabilitation for people with a kneecap (patellar) dislocation.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Professor Afsie Sabokbar retires after more than 30 years at NDORMS

Botnar Institute Director of Graduate Studies, Professor Afsie Sabokbar, is retiring after more than 30 years at NDORMS.

Researchers funded to cure – rather than manage – inflammatory disease

Researchers from the Kennedy Institute of Rheumatology will join international partners in a bid to transform how chronic inflammatory disease is treated.